Literature DB >> 11944634

The fatty liver in AIDS.

Phyllis C Tien1, Carl Grunfeld.   

Abstract

Steatosis or fatty liver in individuals with human immunodeficiency virus (HIV) may result from HIV itself, the use of nucleoside analogues, concurrent infection with hepatitis B or C, alcohol use, diabetes mellitus, obesity, or combinations of these factors. Nucleoside analogues have been the focus of increasing concern, because several fatal cases of severe macrosteatosis, lactic acidosis, and hepatomegaly have been linked to the use of nucleoside analogues. Other classes of antiretroviral drugs, as well as opportunistic infections, can also cause hepatic injury without steatosis. The additive effect of these different risk factors, especially in the presence of underlying hepatic steatosis, likely contributes to the increased prevalence of hepatic abnormalities among HIV-infected individuals. The conditions under which some patients rapidly progress to hepatic failure and/or cirrhosis need to be defined. This is a US government work. There are no restrictions on its use.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11944634

Source DB:  PubMed          Journal:  Semin Gastrointest Dis        ISSN: 1049-5118


  5 in total

1.  Sex differences in the association of HIV infection with hepatic steatosis.

Authors:  Ani Kardashian; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Monika Sarkar; Natalie Korn; Kyle Tillinghast; Marion G Peters; Susan M Noworolski; Phyllis C Tien
Journal:  AIDS       Date:  2017-01-28       Impact factor: 4.177

2.  Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.

Authors:  Valrie Martinez; Thi Dieu Ngan Ta; Zahra Mokhtari; Marguerite Guiguet; Patrick Miailhes; Marc-Antoine Valantin; Frderic Charlotte; Philippe Bertheau; Jean-Michel Molina; Christine Katlama; Eric Caumes
Journal:  BMC Res Notes       Date:  2012-07-09

3.  Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.

Authors:  Richard K Sterling; Melissa J Contos; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Mitchell L Shiffman; Arun J Sanyal
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

4.  The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma.

Authors:  Barbara Renga; Daniela Francisci; Adriana Carino; Silvia Marchianò; Sabrina Cipriani; Maria Chiara Monti; Rachele Del Sordo; Elisabetta Schiaroli; Eleonora Distrutti; Franco Baldelli; Stefano Fiorucci
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

5.  Strong correlation by ultrasonography of hepatomegaly and the presence of co-infection in HIV/HCV cirrhotic patients.

Authors:  Denise Cerqueira Paranaguá Vezozzo; Maria Cassia Mendes-Correa; Marlone Cunha-Silva; Mónica Viviana Alvarado-Mora; João Ítalo Dias França; José Luiz Sebba; Antonio Carlos Nicodemo; Claudia P M S Oliveira; Flair José Carrilho
Journal:  Braz J Infect Dis       Date:  2013-02-27       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.